A share price of AN2 Therapeutics Inc [ANTX] is currently trading at $1.14, up 5.56%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ANTX shares have gain 1.79% over the last week, with a monthly amount glided 8.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
AN2 Therapeutics Inc [NASDAQ: ANTX] stock has seen the most recent analyst activity on August 09, 2024, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $1 from $5. Previously, Evercore ISI downgraded its rating to Underperform on August 09, 2024. On July 03, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $5 on the stock. JMP Securities upgraded its rating to a Mkt Outperform but stick to its price target of $6 on April 02, 2024. Leerink Partners downgraded its rating to a Market Perform and reduced its price target to $7 on February 13, 2024. Oppenheimer downgraded its rating to Perform for this stock on February 12, 2024. In a note dated February 12, 2024, JMP Securities downgraded an Mkt Perform rating on this stock.
AN2 Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.01 and $1.55. Currently, Wall Street analysts expect the stock to reach $7.75 within the next 12 months. AN2 Therapeutics Inc [NASDAQ: ANTX] shares were valued at $1.14 at the most recent close of the market. An investor can expect a potential return of 579.82% based on the average ANTX price forecast.
Analyzing the ANTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -0.48 and Total Capital is -0.56.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0959 points at the first support level, and at 1.0517 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1621, and for the 2nd resistance point, it is at 1.1841.
Ratios To Look Out For
To put it in perspective, the Current Ratio for AN2 Therapeutics Inc [NASDAQ:ANTX] is 9.33. Also, the Quick Ratio is 9.33, while the Cash Ratio stands at 8.62.
Transactions by insiders
Recent insider trading involved Eizen Joshua M, that happened on Nov 04 ’25 when 2819.0 shares were sold. Chief Strategy Officer, Prior Stephen David completed a deal on Nov 04 ’25 to sell 765.0 shares. Meanwhile, 10% Owner Leonard Braden Michael sold 0.2 million shares on May 28 ’25.
